Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors

Eur J Cancer. 2021 May:148:58-60. doi: 10.1016/j.ejca.2021.02.011. Epub 2021 Feb 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Aged
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Breast Neoplasms / complications
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy
  • COVID-19 / complications
  • COVID-19 / diagnosis
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment
  • COVID-19 Nucleic Acid Testing
  • COVID-19 Serological Testing
  • COVID-19 Serotherapy
  • Dexamethasone / therapeutic use
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxychloroquine
  • Immunization, Passive
  • Immunotherapy
  • Latent Infection
  • Lopinavir / therapeutic use
  • Lung Neoplasms / complications
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy
  • Male
  • Molecular Targeted Therapy
  • Neoplasms / complications
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Proportional Hazards Models
  • Risk Factors
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Spain
  • Time Factors
  • Virus Shedding*

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Drug Combinations
  • Glucocorticoids
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Dexamethasone
  • Ritonavir
  • Alanine